Dysregulation of the immune system underlies many autoimmune and inflammatory diseases. While genetic contributions to multiple sclerosis, type 1 diabetes and inflammatory bowel disease (IBD) are being studied, abundant new research highlights the importance of environmental factors. The gut microbiome, a consortium of microbes that colonize the human gastrointestinal tract, has emerged as a critical contributor to disease. Gut bacteria regulate the development and function of the immune system, and have been strongly implicated in IBD and experimental colitis. Recent seminal studies have identified that specific gut bacteria can suppress intestinal inflammation in preclinical models. Thus, development of probiotic therapies for IBD is a promising area of research. Our laboratory has described a leading model system for studying beneficial host-bacterial symbiosis. Bacteroides fragilis, a common member of the human microbiome, ameliorates gut inflammation and treats experimental colitis. We reveal striking new data that B. fragilis directly activates the autophagy pathway, and requires autophagy for its therapeutic activity. Autophagy is a cellular process whereby particles (such as pathogenic bacteria) are degraded and destroyed. Importantly, polymorphisms in autophagy genes are highly linked to human IBD. Our research uncovers a new role for autophagy, as a signaling pathway that is used by beneficial bacteria to mediate protection from colitis. This connection between the gut microbiome and autophagy has not been previously studied, and may have profound implications to the underlying cause(s) of IBD. This project will investigate novel mechanisms by which environmental (microbiome) and genetic (autophagy) factors merge to impact intestinal disease. We will test the innovative hypothesis that genetic defects in autophagy lead to IBD by preventing responses to protective signals from gut bacteria.
Specific aims i nclude: 1) defining the signaling pathways by which B. fragilis activates autophagy;2) understanding how autophagy suppresses intestinal inflammation in preclinical models;3) examining cells from IBD patients with polymorphisms in autophagy genes to elucidate how B. fragilis impacts human immune responses. These studies promise to uncover novel and fascinating interactions between gut bacteria and the immune system, by revealing a previously unappreciated link between the microbiome and autophagy. Upon completion, discoveries from this project will significantly advance our long-term goal of developing a safe and effective treatment for IBD.

Public Health Relevance

Inflammatory bowel disease (IBD) is a major public health problem affecting over 1.5 million in the US, with rates of diagnosis on the rise and no effective cure. Recent research has implicated gut bacteria as an environmental factor in IBD, and our laboratory has pioneered studies into how the microbiome can be harnessed to treat intestinal inflammation. This project will explore fascinating new principles into how genetic and environmental factors cooperatively impact disease, advancing research for a promising probiotic therapy for IBD.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Gastrointestinal Mucosal Pathobiology Study Section (GMPB)
Program Officer
Perrin, Peter J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
California Institute of Technology
Schools of Arts and Sciences
United States
Zip Code
Donaldson, G P; Ladinsky, M S; Yu, K B et al. (2018) Gut microbiota utilize immunoglobulin A for mucosal colonization. Science 360:795-800
Lee, Yun Kyung; Mehrabian, Parpi; Boyajian, Silva et al. (2018) The Protective Role of Bacteroides fragilis in a Murine Model of Colitis-Associated Colorectal Cancer. mSphere 3:
Edelblum, Karen L; Sharon, Gil; Singh, Gurminder et al. (2017) The Microbiome Activates CD4 T-cell-mediated Immunity to Compensate for Increased Intestinal Permeability. Cell Mol Gastroenterol Hepatol 4:285-297
Meisel, Marlies; Mayassi, Toufic; Fehlner-Peach, Hannah et al. (2017) Interleukin-15 promotes intestinal dysbiosis with butyrate deficiency associated with increased susceptibility to colitis. ISME J 11:15-30
Yoo, Bryan B; Mazmanian, Sarkis K (2017) The Enteric Network: Interactions between the Immune and Nervous Systems of the Gut. Immunity 46:910-926
Sharon, Gil; Sampson, Timothy R; Geschwind, Daniel H et al. (2016) The Central Nervous System and the Gut Microbiome. Cell 167:915-932
Donaldson, Gregory P; Lee, S Melanie; Mazmanian, Sarkis K (2016) Gut biogeography of the bacterial microbiota. Nat Rev Microbiol 14:20-32
Chu, Hiutung; Khosravi, Arya; Kusumawardhani, Indah P et al. (2016) Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. Science 352:1116-20
Yang, Yang; Wang, Chunlin; Yang, Qunying et al. (2015) Distinct mechanisms define murine B cell lineage immunoglobulin heavy chain (IgH) repertoires. Elife 4:e09083
Yano, Jessica M; Yu, Kristie; Donaldson, Gregory P et al. (2015) Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 161:264-76

Showing the most recent 10 out of 31 publications